JP Patent

JP7581052B2 — レナリドミドの経口用コーティング錠剤組成物

Assigned to Samyang Holdings Corp · Expires 2024-11-12 · 2y expired

What this patent protects

Patent listed against Balversa.

Drugs covered by this patent

Balversa (ERDAFITINIB) · Johnson & Johnson

Patent Metadata

Patent number: JP7581052B2
Jurisdiction: JP
Classification: —
Expires: 2024-11-12
Drug substance claim: No
Drug product claim: No
Assignee: Samyang Holdings Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.